These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32329353)

  • 21. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations.
    Stacy ZA; Richter SK
    Ther Adv Cardiovasc Dis; 2018 Sep; 12(9):247-262. PubMed ID: 30081727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
    Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM
    Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
    Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
    Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].
    Colonna P; Ammirati F;
    G Ital Cardiol (Rome); 2016 Nov; 17(11):932-939. PubMed ID: 27996999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
    Saliba W
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):323-35. PubMed ID: 26055615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.
    Osmancik P; Herman D; Neuzil P; Hala P; Taborsky M; Kala P; Poloczek M; Stasek J; Haman L; Branny M; Chovancik J; Cervinka P; Holy J; Kovarnik T; Zemanek D; Havranek S; Vancura V; Opatrny J; Peichl P; Tousek P; Lekesova V; Jarkovsky J; Novackova M; Benesova K; Widimsky P; Reddy VY;
    J Am Coll Cardiol; 2020 Jun; 75(25):3122-3135. PubMed ID: 32586585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan　- Insight From the ANAFIE (All Nippon AF In Elderly) Registry.
    Hiasa KI; Kaku H; Inoue H; Yamashita T; Akao M; Atarashi H; Koretsune Y; Okumura K; Shimizu W; Ikeda T; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Kaburagi J; Takita A; Tsutsui H
    Circ J; 2020 Feb; 84(3):388-396. PubMed ID: 31969518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
    Schäfer A; Flierl U; Berliner D; Bauersachs J
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):555-568. PubMed ID: 32350792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
    Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
    Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation.
    Mostaza JM; Suarez C; Cepeda JM; Manzano L; Sánchez D;
    BMC Cardiovasc Disord; 2021 Aug; 21(1):384. PubMed ID: 34372782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
    Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
    J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
    Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
    JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type and doses of oral anticoagulants and adherence to anticoagulant treatment in elderly patients with atrial fibrillation: the ESPARTA study.
    Mostaza JM; Suárez Fernández C; Castilla Guerra L; Suriñach JM; Tamarit JJ; Diaz Diaz JL; García Polo I; Santamaria EF; Fidalgo Fernández MA; de la Guerra Acebal C; Dávila Ramos MF; Ràfols C
    J Comp Eff Res; 2018 Mar; 7(3):223-232. PubMed ID: 29465254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
    Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
    Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.